The NDSU Department of Pharmaceutical Sciences has invited stem cell expert Stephen Bartelmez, founder and CEO of BetaStem, to deliver a research seminar. The presentation, titled “Transient Inhibition of Endogenous TGF-β1 in Human and Murine Stem Cells Enhances their Capacity to Regenerate Damaged Tissue,” is scheduled for Thursday, Oct. 9, at 11 a.m. to 12:15 p.m. in Sudro Hall room 21.
Bartelmez has 28 years of experience with the biology and therapeutic application of human adult stem cells. He received his doctorate in immunohematology from the University of Glasgow, and post-doctoral training from the Bowman-Gray School of Medicine, North Carolina, and Albert Einstein College of Medicine, New York. He discovered the key role of endogenous TGFβ expression in stem cells in human peripheral blood, bone marrow and cord blood.
Bartelmez previously was president and CEO of Ixion Biotechnology Inc. and vice president and director of research for HemoGenix. He also held positions with ViaCell Singapore and was an assistant professor of pathobiology at the University of Washington, where his lab discovered several key regulators of hematopoietic stem cell engraftment.
The seminar is open to all persons interested in biomedical research. For further information, contact Jagdish Singh at 701-231-7943.
NDSU is recognized as one of the nation's top 108 public and private universities by the Carnegie Commission on Higher Education.
